Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.
Fifteen patients with prolonged neutropenia (a median of 23 days with granulocyte [PMN] < or = 500/microliters) and established fungal infections that had not responded to adequate antifungal therapy were transfused with PMN concentrates collected from 35 cytokine-primed granulocyte colony-stimulating factor (GCSF) donors. Patients received a median of six transfusions. Leukocytosis and granulocytosis were observed within 24 hours of the first GCSF injection, which yielded concentrates averaging 55 x 10(9) white blood cells and 41 x 10(9) PMN. Data analysis suggested that response might be related to the duration of neutropenia and known infection, as patients given PMN tx earlier in the infectious course tended to have a better response. No significant toxicity was observed in donors.
Hester
J P
JP
Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Dignani
M C
MC
Anaissie
E J
EJ
Kantarjian
H M
HM
O'Brien
S
S
Freireich
E J
EJ
D016913:Blood Component Transfusion; D001782:Blood Donors; D001800:Blood Specimen Collection / Q000379:methods*; D001855:Bone Marrow Diseases / Q000209:etiology / Q000628:therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006098:Granulocytes / Q000187:drug effects / Q000637:transplantation*; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D009181:Mycoses / Q000150:complications*; D009503:Neutropenia / Q000209:etiology / Q000628:therapy*; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor